Celltrion's Herceptin Biosimilar One Step Closer To US FDA Approval
Executive Summary
Following Oncologic Drugs Advisory Committee's recommendation for Mylan and Biocon's trastuzumab biosimilar, Celltrion and Teva's CT-P6 appear to be one of the next one in, but given the expiry of Herceptin patent in the US and other late stage trastuzumab biosimilar candidates, it could be anybody's game to launch their products first.
You may also be interested in...
Celltrion Hit By Truxima Price Cut, Temporary Utilization Rate Drop
Intensifying competition in the global biosimilars space and a temporary drop in its factory utilization rate took a toll on Celltrion's earnings in the third quarter, but analysts still expect a rosy outlook next year amid the expected US launches of biosimilar rituximab and trastuzumab, and the first subcutaneous version of Remsima on the horizon in Europe.
Celltrion Hit By Truxima Price Cut, Temporary Utilization Rate Drop
Intensifying competition in the global biosimilars space and a temporary drop in its factory utilization rate took a toll on Celltrion's earnings in the third quarter, but analysts still expect a rosy outlook next year amid the expected US launches of biosimilar rituximab and trastuzumab, and the first subcutaneous version of Remsima on the horizon in Europe.
Celltrion's Trastuzumab Biosimilar Gets EC Nod
With the latest EC approval, Celltrion's trastuzumab biosimilar Herzuma is set to compete with Samsung's Ontruzant, which received approval late last year.